Ichnos Sciences Biotherapeutics SA

The spirit of a start-up. The experience of an established biotech. Ichnos (‘ik-noz) Sciences—a name taken from an ancient Greek word for “footprint”—is shifting how the world thinks about innovation in medicine. With a holistic approach to the research, discovery, and development of breakthrough therapies in oncology and autoimmune disease, we bring the courage and passion to take scientific risks and pursue the greatest of challenges.

Based in the U.S., Ichnos Sciences also has two sites in Switzerland, a biological R&D center in Lausanne and a GMP manufacturing and process sciences center in La Chaux-de-Fonds. Our Swiss operations focus on the discovery and development of novel biological entities and drugs, including monoclonal antibodies and bispecific antibodies that are based on our proprietary technology platform, BEAT® (Bispecific Engagement by Antibodies based on the T cell receptor).

We currently have three biologics in clinical development, ranging from Phase 1 to Phase 2b, plus multiple discovery programs. With the molecules and drugs in our pipeline, we are seeking new answers to create life-changing therapies for patients with cancer and autoimmune disease.

Our work is rooted in purpose and aimed at progress. Ichnos Sciences is fast-paced, forward-looking and visionary—a company where science, creativity, and a diversity of ideas thrive. We move quickly and nimbly, working together, challenging and supporting one another and ourselves to go further, look deeper, take scientific risks, shift perspectives, and drive forward the scientific advances that will leave an imprint on the world around us.

We are looking for highly motivated people who thrive on being challenged and working in an agile, collaborative and multicultural environment. If you are intrigued by the idea of joining our multidisciplinary discovery team, and would like to play a key role in advancing rigorous, cutting-edge science, we invite you to join us.

Because cure is possible.